Pembrolizumab for metastatic squamous cell carcinoma arising from mature teratoma of the ovary: A letter to the editor

Eur J Obstet Gynecol Reprod Biol. 2024 Sep:300:372-373. doi: 10.1016/j.ejogrb.2024.07.066. Epub 2024 Jul 31.

Authors

Peter Scalia¹, Gabriel Levin², Susie Lau³

Affiliations

¹ Division of Gynecology Oncology at Jewish General Hospital, McGill University, Montreal, QC, Canada. Electronic address: [email protected].
² Division of Gynecology Oncology at Jewish General Hospital, McGill University, Montreal, QC, Canada. Electronic address: [email protected].
³ Division of Gynecology Oncology at Jewish General Hospital, McGill University, Montreal, QC, Canada. Electronic address: [email protected].

PMID: 39098576
DOI: 10.1016/j.ejogrb.2024.07.066

No abstract available

Publication types

Letter
Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized* / therapeutic use
Antineoplastic Agents, Immunological* / therapeutic use
Carcinoma, Squamous Cell* / drug therapy
Carcinoma, Squamous Cell* / pathology
Carcinoma, Squamous Cell* / secondary
Female
Humans
Ovarian Neoplasms* / drug therapy
Ovarian Neoplasms* / pathology
Teratoma* / drug therapy
Teratoma* / pathology

Substances

pembrolizumab
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological

Supplementary concepts

Teratoma, Ovarian